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bTRIUMF, Vancouver, British Columbia, CanadaOn May 18, 2009, Atomic Energy of Canada Limited
(AECL) announced that the 52-year-old National Research
Universal (NRU) reactor at Chalk River was out of service
after detection of a heavy-water leak in the containment
vessel, and they would not be able to supply several radio-
isotopes, most notably molybdenum 99 (99Mo) used in the
manufacture of 99mTc generators. Because approximately
40%e50% of the world’s supply of 99Mo was produced at
the NRU reactor, this sudden loss threatened the provision of
nuclear medicine studies to millions of patients around the
world. There are approximately 30,000 nuclear medicine
procedures performed every week in Canada at more than
200 nuclear medicine facilities and more than 15,000,000
every year in the United States. More than 70% of those
procedures use 99mTc radiopharmaceuticals. By the end of
May 2009, it became obvious that this would not be a short-
term problem, and, in August, the AECL announced that the
NRU reactor would not return to service before Spring 2010.
To further compound a bad situation, the second largest
supplier of 99Mo in the world, the HFR-Petten reactor in the
Netherlands was shut down for a 4-week routine mainte-
nance in late July, which resulted in even more marked
shortages into late August.
Unfortunately, this was not the first prolonged shutdown
of the NRU reactor. In late 2007, a dispute between the
Canadian Nuclear Safety Commission (CNSC) and AECL
caused an extended outage that eventually resulted in an act
of Parliament (Bill C-38) to allow restarting of the NRU
reactor. Subsequently, several reports examined the issues
and problems surrounding those events, and recommenda-
tions were made to prevent a similar occurrence. A June
2008 report by Talisman International [1] laid the blame on
a culture of informality and interactions that were ‘‘expert
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Health Canada submitted in May 2008 recommended
a made-in-Canada solution that included replacement of the
NRU reactor and diversification of the 99mTc generator
supply in Canada [2].
In recent years, almost all 99Mo for medical uses has been
produced by irradiating uranium targets in just 5 reactors
[3].The largest and most productive reactors have been the
Canadian NRU reactor and the Dutch HFR-Petten reactor.
These 2 reactors accounted for 60%-80% of worldwide
production, although the NRU reactor alone was capable of
supplying up to 80% of the world’s supply of 99Mo. Much
smaller amounts are produced at reactors in Belgium, France,
and South Africa (the Safari reactor). All of these reactors
are aging and are at or even beyond their projected life span,
with the Safari reactor being the newest, at 43 years of age.
For some time, Canada has been preeminent in the world’s
supply of 99Mo by using the NRU reactor. In 1991, MDS
purchased Nordion from the Canadian government, and
a secure long-term medical isotope supply was considered
a key component of that purchase. Nordion acts as the pro-
cessing facility for purification of 99Mo from the NRU
reactor and sells the 99Mo to the generator manufacturers
based in the United States (currently Covidien in St Louis,
MO, and Lantheus in Boston, MA) who supply the entire
North American market. The radiopharmaceutical market is
relatively small, and, because the production of 99Mo has
often benefited from direct government support for research
reactor operations, there has been little impetus or profit for
other suppliers to get into the business of 99Mo production.
As the NRU reactor aged, it was obvious by the mid-
1990s that a replacement would be necessary. In 1996, MDS
Nordion contracted with AECL to construct 2 nuclear reac-
tors and a processing facility at Chalk River (the MAPLE
project) to be operational in 2000. This effectively closed the
door to consideration of other proposals at the time,
including proposals that would have shifted production for
the American market to the United States. Unfortunately, the
MAPLE reactors fell behind schedule and the costs morell rights reserved.
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updated new agreement was reached in 2006 whereby AECL
would bring the MAPLE reactors on line by October 2008
and AECL would supply isotopes to Nordion for 40 years.
The MAPLE reactors have been plagued by an unexplained
positive power coefficient of reactivity (PCR) that has pre-
vented their licensing by CNSC, and, after much investiga-
tion and examination of proposed solutions, AECL and the
Government of Canada announced the discontinuation of the
MAPLE project on May 16, 2008. There has been much
debate surrounding this issue, with a number of scientists
stating that it is safe to run the MAPLE reactors but with
AECL insisting that the positive PCR presents a ‘‘potentially
insurmountable hurdle to safely commissioning the MAPLE
reactors as currently designed.’’ On July 9, 2008, MDS
Nordion filed suit against AECL and the Government of
Canada, seeking $1.6 billion in damages for negligence and
breach of contract [4].
Currently, 99Mo production uses nuclear bomb grade
highly enriched uranium (HEU) targets that contain about
93% uranium 235. HEU is produced in the United States and
has been made available as a target material through a loop
hole in nuclear nonproliferation agreements. With the
continued proliferation of nuclear weapons and terrorism in
recent years, the United States has made it clear that it will
not supply HEU outside the United States for much longer
and has encouraged 99Mo suppliers to switch their produc-
tion to the use of low enriched uranium (LEU) targets that
contain less than 20% uranium 235. The switch to LEU
targets may be expensive and will likely require more
suppliers because of the lower 99Mo yields when bombarding
LEU. Under the Energy Policy Act of 2005, the US Secretary
of Energy contracted with the National Academy of Sciences
to conduct a study on the elimination of HEU targets. This
review was also to evaluate the demand and availability of
medical isotopes in regular domestic use and recommend
various solutions to the problem of repeated shortages. The
Committee on Medical Isotope Production Without Highly
Enriched Uranium included 3 Canadian experts in the field.
Their report, issued in January 2009, concluded that
conversion to LEU targets was possible, although may be
more costly than anticipated and may require government
subsidies [5]. This report also discusses a number of alter-
native sources of the 99Mo supply. It was obvious to the
committee that the supply of 99Mo was tenuous at best and
that reliability of supply was more of an immediate issue to
patient and public welfare than conversion to LEU,
a prediction that was sadly proven to be true only a few
months later when the NRU reactor was shutdown.
There is no quick fix to the problem that nuclear medicine
finds itself in today, but a number of initiatives in both the
United States and Canada are underway to find solutions.
The major commercial suppliers of 99mTc generators, Covi-
dien and Lantheus, have worked tirelessly to try and maxi-
mize the availability of generators in Canada, the United
States, and Europe. Some of the lessons of communication
and cooperation learned at the time of the last crisis in late2007 have helped nuclear medicine suppliers and facilities to
maximize the availability of radioisotopes for patient studies.
In early July 2009, Lantheus received speedy approval from
both Health Canada and the U.S. Food and Drug Adminis-
tration for the use of 99Mo from the new Australian Nuclear
Science and Technology Organisation OPAL reactor that
uses LEU fuel and targets. Unfortunately, this reactor was
originally intended only to provide 99Mo for the local
Australia and New Zealand markets, and is only capable of
providing a fraction of current shortfalls in the world supply.
Covidien with Babcock and Wilcox (a large nuclear industry
company in the United States) entered into an agreement in
January 2009 to develop a new production system by using
a reactor in which LEU is used as both fuel and target in an
aqueous solution, with 99Mo being extracted from the liquid-
phase fuel [6]. This is envisioned as a low-power reactor that
produces minimal radioactive waste. However, even with
several reactors of this size, it is anticipated that they would
only supply 50% of the current US demand, and the project
is several years from being operational. Recently, MDS
Nordion announced an agreement to study the feasibility of
obtaining 99Mo from the Karpov Institute of Physical
Chemistry in Moscow, which currently provides most of the
99mTc generators for the domestic Russian market. It is
estimated that once tooled up, they might be able to supply
an additional 10%-15% of the world market.
A report of the Society of Nuclear Medicine (SNM)
Isotope Availability Task Force issued, in updated draft form,
on February 23, 2009, identified several existing reactors
which could be used to supply 99Mo [7]. The University of
Missouri Research Reactor (MURR), with only minor
changes, could supply 50% of the US market and may be the
easiest current alternative. However, it will take 3e4 years
for MURR to build the appropriate processing facilities to
handle this volume. A proposal to develop 99Mo production
by using LEU solution targets at the University of California
at Davis in the McClellan Nuclear Radiation Center reactor
could also reach the commercial production stage in 3-4
years. Several other US Department of Energy (DOE) and
university research reactors could supply much of the US
demand for 99Mo but would require major construction or
development projects and/or significant changes in their
current missions and approvals and licensing and would
require more than 5 years to implement.
On July 10, 2009, a White Paper on the supply of 99Mo
was published by a coalition of the SNM and 8 other
professional organizations in the United States [8]. The
coalition strongly advocated a domestic production capa-
bility that would ensure availability of nuclear medicine
studies for their patients, even in the unlikely event of
a complete closing of the US border to any radioactive
shipments. They argued for a public-private partnership to
develop domestic production of 99Mo as quickly as possible
and particularly highlighted the MURR and Babcock and
Wilcox options. The need for co-operation from regulatory
authorities was also discussed, and they strongly urged that
any change from HEU to LEU targets be undertaken only if
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nology has been proven and financial and regulatory support
is in place.
There seems little doubt now that the United States will
proceed as rapidly as possible to develop a made-in-the-US
approach that will ensure adequate supplies of 99Mo for
American patients. On July 21, Representatives Edward
Markey and Fred Upton introduced the American Medical
Isotopes Production Act of 2009 (H.R. 3276) in the House of
Representatives in the US Congress [9]. This bill will
provide the resources and authority to the DOE to bring
domestic production of 99Mo in the United States online as
soon as possible. The bill allocates $163 million over 5 years,
which fully funds the DOE cost projections for creating
a robust domestic production capacity for 100% of their
99Mo needs. Furthermore, the bill will end all exports of
HEU within 7 years (2017) and asks the Nuclear Regulatory
Commission to review and report on all previous HEU
exports from the United States. The licensed use of HEU
targets in the United States will be allowed, but the programs
must actively support the development of alternative targets.
Finally, the bill mandates the National Academy of Sciences
to issue a report within 5 years on all 99Mo production
facilities and to assess the progress on eliminating HEU
targets worldwide. This bill is strongly supported by the
SNM and a coalition of other organizations as well as the 2
main commercial suppliers of 99mTc generators.
On the Canadian side of the border, there are attempts
being made by the government to both develop alternative
supplies of 99Mo and foster alternatives to 99Mo-99mTc based
radiopharmaceuticals by switching to the use of other
isotopes, including cyclotron-produced isotopes such as
thallium 201 and positron emitters used in positron emission
tomography studies. The Canadian Association of Nuclear
Medicine and Canadian Medical Association have made
a number of presentations to various government agencies
and departments outlining the efforts being made in Cana-
dian nuclear medicine facilities to maintain services for
patients despite the shortages. This has included reschedul-
ing patients to best fit the availability of 99mTc generators,
which has occasionally meant more overtime and weekend
appointments. As a whole, these changes and day-to-day
flexibility have meant that patient nuclear medicine services
have been maintained, especially for urgent studies, and that
wait lists have not grown substantially in most provinces,
although there are some persisting disparities of supply in
certain areas of the country.
Both the Canadian Ministry of Natural Resources and
Ministry of Health have been very active in dealing with the
current crisis, by building on strategies developed during the
last shortage. The government has been at the forefront of
international efforts to effect solutions and coordinate
radioisotope production through the Nuclear Energy Agency
of the Organization for Economic Cooperation and Devel-
opment (OECD). The Canadian government initiated an
OECD meeting on radioisotope availability in January 2009
in Paris and chaired the first meeting of the OECD’s HighLevel Group on Security of Supply of Medical Isotopes in
Toronto in June 2009. In May 2009, the Ontario and Cana-
dian governments announced $22 million in infrastructure
funds for McMaster University to upgrade the university’s
research reactor and expand Canada’s isotope research and
production capabilities. Still, this is also a 50-year-old
reactor and would use HEU targets. The SNM report on
isotope availability noted that even with 24/7 operation, it is
estimated that they could only supply about 30% of North
American 99Mo needs. Its role is most likely to be a backup
supplier rather than a primary source. On June 14, 2009, the
federal Minister of Health announced the appointment of
Alexander (Sandy) McEwan, an internationally respected
nuclear medicine physician from the Cross Cancer Institute
in Edmonton, as special advisor on medical isotopes to the
minister. Two days later, the Minister of Health with the
Canadian Institutes of Health Research and the Natural
Sciences and Engineering Research Council announced the
availability of $6 million in funding for proposals that would
help reduce the dependence of nuclear medicine studies on
reactor-sourced 99mTc.
On June 19, 2009, an Expert Review Panel was announced
by the Ministries of Health and Natural Resources and was
mandated to assess proposals to secure a reliable radioisotope
supply for Canada in the medium and long terms. By the
deadline of July 31, 2009, there were 22 expressions of interest
received, and the panel is to report by November 30, 2009
[10]. A number of proposals have already been made public.
MDS Nordion submitted a proposal to the expert
committee to complete and bring into service the MAPLE
reactors within 24 months by using the assistance of the
South African Nuclear Energy Corporation, which operates
the SAFARI reactor. It is argued that that use of different
computer codes to model the reactor performance might
resolve the discrepancy between the models and the actual
reactor performance and that this would allow licensing of
the reactors by CNSC [11]. Previous calls by MDS Nordion
to complete the MAPLE project have been met by AECL
claims that resolution of the PCR problem in the reactors
might be impossible and that a best-case scenario would still
be at least 5e6 more years. As well, proposals to redesign
and replace the cores of the MAPLE reactors (costs esti-
mated by MDS Nordion at tens of millions of dollars) have
been countered by AECL statements that this would require
7e10 years to complete.
The Province of Saskatchewan in partnership with the
University of Saskatchewan has also submitted a proposal to
the panel. As the world’s largest producer of uranium and
home of the Canadian Light Source synchrotron, Saskatch-
ewan has proposed a new research reactor, the Canadian
Neutron Source facility, to serve the needs for both
production of medical isotopes and for research in neutron-
based science. Total costs are estimated at $500e$750
million, with completion by 2016.
There are a number of nonreactor-based proposals.
Advanced Cyclotron Systems Incorporated of British Columbia
proposed producing 99mTc directly by use of 24 MeV cyclotrons
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Estimates are that, for a 6-hour irradiation, almost 2 TBq of
99mTc could be produced. Although this nongenerator solution
requires daily production, being able to produce 99mTc several
times a day could meet the needs of nearby regional centers and
allow for scarce generators to be used in more distant locations.
Another proposal is an accelerator-based plan from the Prairie
Isotope Production Enterprise at the University of Winnipeg that
might be able to supply Canada’s needs, for a total investment of
$35 million within 3 years.
One of the most innovative suggestions in the recent past
has come from the TRIUMF facility in Vancouver. Even
before the current crisis, TRIUMF proposed a project to
examine the production of 99Mo by photon fission of
uranium 238 by using photons from an electron accelerator
[12]. Unfortunately, 99Mo yields are low, which necessitates
multiple units to supply the world’s needs, and the tech-
nology is as yet unproven. In April 2009, MDS Nordion and
TRIUMF signed an agreement to study the feasibility of
producing photon fission 99Mo for the global isotope market
by building on the 30-year university-industry relationship
between them. A formal submission by the 2 partners to the
expert panel proposes the use of superconducting radio-
frequency electron accelerators to achieve technical
demonstration of principle of the method by 2012 and
commercial production by 2015. It is projected that one such
system could supply 100% of the Canadian domestic market
for 99Mo and would cost approximately $50 million.
It took a few years to reach the situation we find ourselves
in today, and it will be several more years to reach stability
again. Many lessons have been learned, not least of which is
to ensure a diversity of supply that will be prevent any future
recurrences. Although 99Mo generators and thus 99mTc
radiopharmaceuticals were relatively cheap in the past, we
are likely to see significant increases in the cost of 99mTc
products in the future, regardless of the solutions developed.
Over the last few months, we have all witnessed an
extraordinary degree of cooperation and understanding
between commercial suppliers, government agencies and
ministries, hospitals, nuclear medicine facilities, physicians,
and even our patients. This has helped to ensure that the
provision of nuclear medicine services continues through this
current shortage with as little disruption as possible for our
patients. Although the current situation may continue for
another 6e9 months, we look forward to both medium-termsolutions next year (restarting the NRU reactor) and long-
term solutions for the isotope supply issues as they evolve
over the next 5e10 years.References
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